Bone Marrow Transplant
Fidaxomicin for Prophylaxis Against Clostridium Difficile-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation (2634)
DEFLECT-1: A Phase 3b Multi-Center, Double-Blind, Randomized, Placebo Controlled Study to Demonstrate the Safety and Efficacy of Fidaxomicin for Prophylaxis against CLostridium difficilE-Associated Diarrhea in Adults Undergoing Hematopoietic Stem Cell Transplantation
|Closed||Hematologic Malignancies||Phase III||
The objective of this study is to demonstrate the efficacy and safety of fidaxomicin versus placebo for prophylaxis against Clostridium difficile-Associated Diarrhea (CDAD) in adult subjects undergoing hematopoietic stem cell transplantation (HSCT).
Eligibility Criteria (must meet the following to participate in this study)
- Male or female 18 years of age or older.
- Female subjects of childbearing potential must be using an adequate and reliable method of contraception (e.g., abstinence, barrier with additional spermicide foam or jelly, intrauterine device, hormonal contraception). Subjects (both male and female) must agree to avoid conception during treatment and for four weeks following the end of study treatment.
- Individuals undergoing HSCT with fluoroquinolone prophylaxis.
- Informed consent is provided.
Exclusions (conditions that would prevent participation in this study)
- Ongoing active CDAD infection (as evidenced by clinical signs of diarrhea along with the presence of either toxin A and/or B [or their respective genes, tcdA and/or tcdB] of C. difficile in the stool) or current treatment for CDAD.
- Undergoing cord blood transplants.
- Subject has fulminant colitis, toxic megacolon, or ileus.
- A history of inflammatory bowel disease (ulcerative colitis or Crohn's disease).
- Women who are pregnant or are actively breast feeding (all women of childbearing potential must have a negative pregnancy test result prior to dosing study drug).
- Use of any drugs potentially useful in the treatment of CDAD (e.g. oral vancomycin, metronidazole, oral bacitracin, fusidic acid, rifaximin, and nitazoxanide).
- Any other condition that, in the opinion of the investigator, would jeopardize the safety or rights of the subject participating in the study, would make it unlikely for the subject to complete the study, or would confound the results of the study.
- Participation in other clinical research studies utilizing an investigational agent within one month prior to screening and during the study treatment period.
Last UpdatedSeptember 12, 2014
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.
- Talk to your health care providers first before making decisions about your health care.
- Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.